BioSig Technologies Files 8-K with Corporate Updates

TL;DR

BioSig 8-K: Director changes, officer appointments, bylaws updated, and financials filed. Major corporate housekeeping.

AI Summary

BioSig Technologies, Inc. filed an 8-K on September 5, 2025, reporting on several key events. These include the departure of directors or officers, the election of new directors, the appointment of certain officers, and updates regarding compensatory arrangements. The filing also covers amendments to articles of incorporation or bylaws, changes in the fiscal year, and the submission of matters to a vote of security holders. Additionally, it includes financial statements and exhibits.

Why It Matters

This 8-K filing signals significant corporate governance and operational changes within BioSig Technologies, Inc., which could impact its strategic direction and investor relations.

Risk Assessment

Risk Level: medium — The filing indicates potential shifts in leadership and corporate structure, which can introduce uncertainty and affect business operations.

Key Players & Entities

• BioSig Technologies, Inc. (company) — Registrant
• September 5, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-38659 (filing_id) — SEC File Number
• 26-4333375 (tax_id) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The Nasdaq Stock Mar

Filing Documents

• form8-k.htm (8-K) — 69KB
• ex3-1.htm (EX-3.1) — 12KB
• ex10-1.htm (EX-10.1) — 183KB
• 0001641172-25-026749.txt ( ) — 470KB
• bsgm-20250905.xsd (EX-101.SCH) — 3KB
• bsgm-20250905_lab.xml (EX-101.LAB) — 33KB
• bsgm-20250905_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

03

Item 5.03 Amendment to Articles of Incorporation or Bylaws As described in Item 5.07 below, the stockholders of the Company voted to, among other things, approve the Company's Ninth Amendment to the Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company's common stock from 200,000,000 to 500,000,000 (the "Ninth Certificate of Amendment"). The additional common stock authorized by the Ninth Certificate of Amendment has rights identical to the Company's currently outstanding common stock. The Company filed the Ninth Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on September 5, 2025. The foregoing description of the Ninth Certificate of Amendment does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the full text of the Ninth Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K. Item 5.07 Submission of Matters to a Vote of Security Holders. As of the record date of July 30, 2025, holders of record of the Company's common stock were entitled to one vote per share, totaling 31,326,659 votes, and certain holders of record of the Company's Series C Convertible Preferred Stock, subject to the beneficial stock, were entitled to an aggregate of 354,818 votes. At the Company's Special Meeting, the Company's stockholders voted on Proposal 2, Proposal 3, Proposal 4, Proposal 5 and Proposal 6, each as set forth below. For more information about the foregoing proposals, see the Proxy Statement. The Special Meeting was then adjourned, pending Nasdaq approval, on Proposal 1, the proposal to approve the issuance of approximately 109,070,079 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), subject to

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: September 5, 2025 By: /s/ Karl Henry McPhie Name: Karl Henry McPhie Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR